» Authors » E Jeffrey North

E Jeffrey North

Explore the profile of E Jeffrey North including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 517
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Destache C, Isern R, Kenny D, El-Herte R, Plambeck R, Palmer C, et al.
Antibiotics (Basel) . 2024 Nov; 13(11). PMID: 39596718
ECMO is becoming widely used as a life-saving measure for critically ill patients. However, there is limited data on pharmacokinetics and the dosing of beta-lactam antibiotics in ECMO. In this...
2.
North E, Schwartz C, Zgurskaya H, Jackson M
Expert Opin Drug Discov . 2023 May; 18(7):707-724. PMID: 37226498
Introduction: Tuberculosis and nontuberculous mycobacterial infections are notoriously difficult to treat, requiring long-courses of intensive multi-drug therapies associated with adverse side effects. To identify better therapeutics, whole cell screens have...
3.
Bhattarai P, Hegde P, Li W, Prathipati P, Stevens C, Yang L, et al.
J Med Chem . 2022 Dec; 66(1):170-187. PMID: 36563291
Tuberculosis (TB), caused by (), is one of the leading causes of death in developing countries. Non-tuberculous mycobacteria (NTM) infections are rising and prey upon patients with structural lung diseases...
4.
Gumireddy A, Christman R, Kumari D, Tiwari A, North E, Chauhan H
AAPS PharmSciTech . 2019 Mar; 20(4):145. PMID: 30887133
Curcumin and resveratrol are natural compounds with significant anticancer activity; however, their bioavailability is limited due to poor solubility. This study aimed to overcome the solubility problem by means of...
5.
Li W, Stevens C, Pandya A, Darzynkiewicz Z, Bhattarai P, Tong W, et al.
ACS Infect Dis . 2019 Mar; 5(6):1001-1012. PMID: 30882198
MmpL3, an essential transporter involved in the export of mycolic acids, is the proposed target of a number of antimycobacterial inhibitors under development. Whether MmpL3 serves as the direct target...
6.
Pandya A, Prathipati P, Hegde P, Li W, Graham K, Mandal S, et al.
Antimicrob Agents Chemother . 2019 Jan; 63(3). PMID: 30602519
Nontuberculous mycobacteria (NTM) pathogens particularly infect patients with structural lung disorders. We previously reported novel indole-2-carboxamides (ICs) that are active against a wide panel of NTM pathogens. This study discloses...
7.
Li W, Yazidi A, Pandya A, Hegde P, Tong W, Calado Nogueira de Moura V, et al.
Front Microbiol . 2018 Jul; 9:1547. PMID: 30042757
Nontuberculous mycobacterial (NTM) pulmonary infections are emerging as a global health problem and pose a threat to susceptible individuals with structural or functional lung conditions such as cystic fibrosis, chronic...
8.
Pandya A, Villa E, North E
Tetrahedron Lett . 2017 Oct; 58(13):1276-1279. PMID: 28983131
A simple and efficient approach for the synthesis of 2-aminoquinazoline derivatives in moderate to good yields. This reaction employs mild reaction conditions, is metal-free and utilizes readily available starting materials...
9.
Franz N, Belardinelli J, Kaminski M, Dunn L, Calado Nogueira de Moura V, Blaha M, et al.
Bioorg Med Chem . 2017 May; 25(14):3746-3755. PMID: 28545813
Current treatment regimens for non-tuberculous mycobacteria (NTM) and tuberculosis (TB) generally require long duration of therapy with multiple drugs, some of which are broad spectrum antibiotics. Despite some advances in...
10.
Li W, Sanchez-Hidalgo A, Jones V, Calado Nogueira de Moura V, North E, Jackson M
Antimicrob Agents Chemother . 2017 Jan; 61(4). PMID: 28115355
A number of inhibitors of the essential mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of...